BioNano Genomics (NASDAQ:BNGO) will announce its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.57) per share for the quarter.
BioNano Genomics (NASDAQ:BNGO) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.12). The company had revenue of $1.85 million for the quarter, compared to the consensus estimate of $1.76 million. On average, analysts expect BioNano Genomics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ:BNGO remained flat at $$2.25 during trading on Tuesday. 6,053 shares of the stock traded hands, compared to its average volume of 5,328. The stock has a market cap of $24.41 million and a PE ratio of -0.86. The company has a quick ratio of 5.64, a current ratio of 5.94 and a debt-to-equity ratio of 3.13. BioNano Genomics has a twelve month low of $2.01 and a twelve month high of $10.00. The firm’s 50-day moving average price is $2.57.
Several analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of BioNano Genomics from a “hold” rating to a “sell” rating in a research report on Monday, July 8th. Maxim Group set a $7.00 price objective on shares of BioNano Genomics and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, ValuEngine upgraded shares of BioNano Genomics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
BioNano Genomics Company Profile
Bionano Genomics, Inc operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics.
Featured Story: Preferred Stock
Receive News & Ratings for BioNano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.